TrialPaediatric drugs2024

CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus.

Fernando Ferrero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.